Peng Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peng Gao has a total of 347 co-authors. Here are the top co-authors by number of shared publications:
Hui Zhang
Department of Pathology Qilu Hospital and School of Basic Medical Sciences Shandong University Jinan 250000 China
21 shared publicationsRan-Ran Ma
Key Laboratory for Experimental Teratology of the Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China
18 shared publicationsXu Chen
Key Laboratory for Experimental Teratology of Ministry of Education, Department of Pathology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China
18 shared publicationsHai-Ting Liu
Key Laboratory for Experimental Teratology of the Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, PR China
15 shared publicationsDuan-Bo Shi
Department of Pathology, Qilu Hospital, Shandong University, Jinan, China
14 shared publicationsYa-Wen Wang
Department of Pathology, Qilu Hospital of Shandong University, Jinan, China
14 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1831252
Multimodal deep learning for prediction of postoperative recurrence in clear cell renal cell carcinoma: a clinical-radiologic-pathologic approach
Purpose: This study intends to develop and validate a multiclass system that efficiently integrates complementary information from patients’ multimodal data (clinical, imaging, and pathological) to identify individuals at a high risk of 5-year postoperative recurrence among patients with clear cell renal cell carcinoma (ccRCC). Methods: This retrospective multicenter study enrolled 270 clear cell renal cell carcinoma (ccRCC) patients, allocating 215 (79.6%) for model development/validation and 55 (20.4%) to an independent test cohort. Patients were categorized into recurrence and non-recurrence groups based on whether tumor recurrence occurred within 5 years after surgery. The final included case in this cohort underwent surgery in July 2018. Single-modality models were created using radiomics, deep learning (ResNet34), and deep features-based radiomics. Subsequently, multi-modality models were constructed by combining the predicted probabilities from the single-modality models and transferring them to another classifier. All models was assessed using the area under the receiver operating characteristic curve (AUROC). Results: A total of 25 classification models were constructed. Notably, single-modality fusion models generally outperform their radiomics and deep learning-based radiomics (DL) counterparts. Among five single-modality fusion models, the Fused_Non-enhanced model demonstrates best predictive performance, achieving an AUROC value of 0.837 (95% confidence interval [CI]: 0.729-0.946). Similarly, multi-modality radiomics or DL models exhibit superior performance compared to single-modality counterparts. The multi-modality radiomics-DL model demonstrates the highest prediction performance, achieving an AUROC value of 0.967 (95% CI: 0.929-1.0) in the independent testing dataset. Conclusion: The multi-modality radiomics-DL model demonstrates high accuracy in predicting the 5-year postoperative recurrence risk of clear cell renal cell carcinoma (ccRCC).
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1831252
Open AccessMultimodal deep learning for prediction of postoperative recurrence in clear cell renal cell carcinoma: a clinical-radiologic-pathologic approach
Purpose: This study intends to develop and validate a multiclass system that efficiently integrates complementary information from patients’ multimodal data (clinical, imaging, and pathological) to identify individuals at a high risk of 5-year postoperative recurrence among patients with clear cell renal cell carcinoma (ccRCC). Methods: This retrospective multicenter study enrolled 270 clear cell renal cell carcinoma (ccRCC) patients, allocating 215 (79.6%) for model development/validation and 55 (20.4%) to an independent test cohort. Patients were categorized into recurrence and non-recurrence groups based on whether tumor recurrence occurred within 5 years after surgery. The final included case in this cohort underwent surgery in July 2018. Single-modality models were created using radiomics, deep learning (ResNet34), and deep features-based radiomics. Subsequently, multi-modality models were constructed by combining the predicted probabilities from the single-modality models and transferring them to another classifier. All models was assessed using the area under the receiver operating characteristic curve (AUROC). Results: A total of 25 classification models were constructed. Notably, single-modality fusion models generally outperform their radiomics and deep learning-based radiomics (DL) counterparts. Among five single-modality fusion models, the Fused_Non-enhanced model demonstrates best predictive performance, achieving an AUROC value of 0.837 (95% confidence interval [CI]: 0.729-0.946). Similarly, multi-modality radiomics or DL models exhibit superior performance compared to single-modality counterparts. The multi-modality radiomics-DL model demonstrates the highest prediction performance, achieving an AUROC value of 0.967 (95% CI: 0.929-1.0) in the independent testing dataset. Conclusion: The multi-modality radiomics-DL model demonstrates high accuracy in predicting the 5-year postoperative recurrence risk of clear cell renal cell carcinoma (ccRCC).
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Data from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Circular RNA (circRNA), usually produced through a back-splicing process, is a type of single-stranded RNA that is covalently bonded. Our research indicated that a spliceosome composed of SF3B4 and QKI promoted the back-splicing of FNDC3B, thereby promoting the generation of circRNA FNDC3B (Circ-FNDC3B). Circ-FNDC3B is underexpressed in breast cancer and is characterized by a high metastatic risk. In addition, Circ-FNDC3B expression was reduced in breast cancer with larger tumor diameter, later clinical staging, and lymph node metastasis. The secondary structure of Circ-FNDC3B, specifically the 356 to 425 bp sequence, interacts with the biotin carboxylase domain of pyruvate carboxylase (PC), inhibiting the activity of PC. Low expression of Circ-FNDC3B enhances the activity of PC, thereby facilitating cell proliferation. The underlying mechanism involves the promotion of aspartate synthesis and the acceleration of the citrate-pyruvate cycle. This, in turn, promotes NADPH synthesis, thus alleviating the oxidative damage induced by reactive oxygen species. Furthermore, in human breast cancer organoids and a mouse model of lung metastasis, we have validated that exogenous expression of Circ-FNDC3B can inhibit the activity of PC, thereby suppressing tumor proliferation and promoting tumor cell apoptosis. In general, upregulating the expression of Circ-FNDC3B can impede the progression of breast cancer.Implications:This study reveals significant heterogeneity in the expression of circRNAs commonly used to identify breast cancer metastasis and confirms that circRNAs affect the metabolic state of breast cancer through their binding proteins.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Circular RNA (circRNA), usually produced through a back-splicing process, is a type of single-stranded RNA that is covalently bonded. Our research indicated that a spliceosome composed of SF3B4 and QKI promoted the back-splicing of FNDC3B, thereby promoting the generation of circRNA FNDC3B (Circ-FNDC3B). Circ-FNDC3B is underexpressed in breast cancer and is characterized by a high metastatic risk. In addition, Circ-FNDC3B expression was reduced in breast cancer with larger tumor diameter, later clinical staging, and lymph node metastasis. The secondary structure of Circ-FNDC3B, specifically the 356 to 425 bp sequence, interacts with the biotin carboxylase domain of pyruvate carboxylase (PC), inhibiting the activity of PC. Low expression of Circ-FNDC3B enhances the activity of PC, thereby facilitating cell proliferation. The underlying mechanism involves the promotion of aspartate synthesis and the acceleration of the citrate-pyruvate cycle. This, in turn, promotes NADPH synthesis, thus alleviating the oxidative damage induced by reactive oxygen species. Furthermore, in human breast cancer organoids and a mouse model of lung metastasis, we have validated that exogenous expression of Circ-FNDC3B can inhibit the activity of PC, thereby suppressing tumor proliferation and promoting tumor cell apoptosis. In general, upregulating the expression of Circ-FNDC3B can impede the progression of breast cancer.Implications:This study reveals significant heterogeneity in the expression of circRNAs commonly used to identify breast cancer metastasis and confirms that circRNAs affect the metabolic state of breast cancer through their binding proteins.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Figure S6. Impaired PC activity hinders aspartate synthesis in breast cancer
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Figure S6. Impaired PC activity hinders aspartate synthesis in breast cancer
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Primers and interference sequences
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Primers and interference sequences
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Figure S3. Factors Influencing the Low Expression of Circ-FNDC3B in Breast Cancer
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Figure S3. Factors Influencing the Low Expression of Circ-FNDC3B in Breast Cancer
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Relationship between FNDC3B expression and clinicopathological parameters
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SF3B4-QKI Splicing Complex Generates Circ-FNDC3B and Mediates Breast Cancer Inhibition
Relationship between FNDC3B expression and clinicopathological parameters
- Open Access
- 29 May 2026
- Published by Elsevier in SSRN Electronic Journal
A dual-targeted probe of mitochondria and lysosomes based on fluorescence lifetime imaging for visualizing cellular damage and autophagy processes
The dynamic interplay between mitochondria and lysosomes, particularly through the process of mitophagy, serves as a pivotal mechanism for sustaining cellular homeostasis. Fluorescence Lifetime Imaging Microscopy (FLIM) offers a powerful tool to probe intracellular biophysical properties with nanoscale resolution. Herein, a dual-targeted probe (QNN) of mitochondria and lysosomes based on fluorescence lifetime imaging for visualizing cellular damage and autophagy was reported. QNN adopts a typical D-π-A structure, with N-alky-pyridinium cation as acceptor which also facilitates efficient aqueous solubility and mitochondria targeting. Especially, benefiting from the auxiliary terminal -NH₃⁺ moiety, QNN exhibits exceptional pH sensitivity and enables precise discrimination between the strongly acidic lysosomal lumen and the weakly basic mitochondrial matrix with nanosecond-level resolution via FLIM. This capability allows for tracing cellular damage processes and real-time monitoring of fluorescence lifetime changes in mitochondria and lysosomes during autophagy. This work establishes a novel method for visualizing and quantitatively analyzing lifetime alterations associated with cellular injury, while also providing fresh insights into the crosstalk between mitochondria and lysosomes during autophagy.
- 29 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA dual-targeted probe of mitochondria and lysosomes based on fluorescence lifetime imaging for visualizing cellular damage and autophagy processes
The dynamic interplay between mitochondria and lysosomes, particularly through the process of mitophagy, serves as a pivotal mechanism for sustaining cellular homeostasis. Fluorescence Lifetime Imaging Microscopy (FLIM) offers a powerful tool to probe intracellular biophysical properties with nanoscale resolution. Herein, a dual-targeted probe (QNN) of mitochondria and lysosomes based on fluorescence lifetime imaging for visualizing cellular damage and autophagy was reported. QNN adopts a typical D-π-A structure, with N-alky-pyridinium cation as acceptor which also facilitates efficient aqueous solubility and mitochondria targeting. Especially, benefiting from the auxiliary terminal -NH₃⁺ moiety, QNN exhibits exceptional pH sensitivity and enables precise discrimination between the strongly acidic lysosomal lumen and the weakly basic mitochondrial matrix with nanosecond-level resolution via FLIM. This capability allows for tracing cellular damage processes and real-time monitoring of fluorescence lifetime changes in mitochondria and lysosomes during autophagy. This work establishes a novel method for visualizing and quantitatively analyzing lifetime alterations associated with cellular injury, while also providing fresh insights into the crosstalk between mitochondria and lysosomes during autophagy.
- Open Access
- 18 May 2026
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 31 (1)
m6A-modificated Linc00707 promotes the progression of TNBC via U2AF2-mediated alternative splicing of ATG4B
Triple-negative breast cancer (TNBC) represents a clinically aggressive breast cancer subtype with limited therapeutic options. Emerging evidence suggests that long intergenic noncoding RNA 00707 (Linc00707) plays a role in TNBC; however, the upstream regulators governing Linc00707 expression and the mechanisms by which it contributes to tumor progression remain largely undefined. The FOXP3-mediated transcriptional regulation of Linc00707 was analyzed using chromatin immunoprecipitation and luciferase reporter assays. The post-transcriptional regulation of Linc00707 was examined by RNA immunoprecipitation (RIP), methylated RIP, and RNA pull-down assays to assess WTAP-dependent m6A modification, IGF2BP2-mediated stabilization, and U2AF2 interaction. RNA sequencing and biochemical analyses were used to identify downstream regulatory pathways. The binding of oligo-anti-Linc00707 to Linc00707 and its ability to disrupt U2AF2 association were confirmed by RIP and RNA fluorescence in situ hybridization (RNA-FISH). Cellular assays and nude mouse xenograft models were employed to evaluate functional and therapeutic effects. FOXP3 was found to transcriptionally activate Linc00707 through direct promoter binding. The WTAP-mediated m6A modification enhanced the IGF2BP2-dependent stabilization of Linc00707. In the nucleus, Linc00707 interacted with the splicing factor U2AF2, with nucleotides 1-593 identified as a critical interaction region. Building on this observation, we further showed that the Linc00707-U2AF2 interaction functionally controls U2AF2 expression and stability via FOXP3. The Linc00707-U2AF2 complex was associated with altered alternative splicing of the autophagy-related gene ATG4B, contributing to enhanced TNBC cell proliferation, invasion, and autophagy suppression. Importantly, oligonucleotides complementary to the U2AF2-binding region of Linc00707 (oligo-anti-Linc00707) disrupted this interaction, attenuated Linc00707-driven oncogenic phenotypes, and restored autophagic activity. In vivo, oligo-anti-Linc00707 treatment significantly reduced tumor growth, supporting its therapeutic potential in TNBC. FOXP3 activates Linc00707 transcription in TNBC. WTAP-mediated m6A modification enhances Linc00707 stability via IGF2BP2. Linc00707 recruits U2AF2 to drive oncogenic ATG4B splicing, promoting tumor progression. Oligo-anti-Linc00707 specifically blocks Linc00707-U2AF2 complex formation, reversing its tumor-promoting and autophagy-suppressing functions. Thus, targeting Linc00707 represents a promising therapeutic strategy for TNBC.
- 18 May 2026
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 31 (1)
Open Accessm6A-modificated Linc00707 promotes the progression of TNBC via U2AF2-mediated alternative splicing of ATG4B
Triple-negative breast cancer (TNBC) represents a clinically aggressive breast cancer subtype with limited therapeutic options. Emerging evidence suggests that long intergenic noncoding RNA 00707 (Linc00707) plays a role in TNBC; however, the upstream regulators governing Linc00707 expression and the mechanisms by which it contributes to tumor progression remain largely undefined. The FOXP3-mediated transcriptional regulation of Linc00707 was analyzed using chromatin immunoprecipitation and luciferase reporter assays. The post-transcriptional regulation of Linc00707 was examined by RNA immunoprecipitation (RIP), methylated RIP, and RNA pull-down assays to assess WTAP-dependent m6A modification, IGF2BP2-mediated stabilization, and U2AF2 interaction. RNA sequencing and biochemical analyses were used to identify downstream regulatory pathways. The binding of oligo-anti-Linc00707 to Linc00707 and its ability to disrupt U2AF2 association were confirmed by RIP and RNA fluorescence in situ hybridization (RNA-FISH). Cellular assays and nude mouse xenograft models were employed to evaluate functional and therapeutic effects. FOXP3 was found to transcriptionally activate Linc00707 through direct promoter binding. The WTAP-mediated m6A modification enhanced the IGF2BP2-dependent stabilization of Linc00707. In the nucleus, Linc00707 interacted with the splicing factor U2AF2, with nucleotides 1-593 identified as a critical interaction region. Building on this observation, we further showed that the Linc00707-U2AF2 interaction functionally controls U2AF2 expression and stability via FOXP3. The Linc00707-U2AF2 complex was associated with altered alternative splicing of the autophagy-related gene ATG4B, contributing to enhanced TNBC cell proliferation, invasion, and autophagy suppression. Importantly, oligonucleotides complementary to the U2AF2-binding region of Linc00707 (oligo-anti-Linc00707) disrupted this interaction, attenuated Linc00707-driven oncogenic phenotypes, and restored autophagic activity. In vivo, oligo-anti-Linc00707 treatment significantly reduced tumor growth, supporting its therapeutic potential in TNBC. FOXP3 activates Linc00707 transcription in TNBC. WTAP-mediated m6A modification enhances Linc00707 stability via IGF2BP2. Linc00707 recruits U2AF2 to drive oncogenic ATG4B splicing, promoting tumor progression. Oligo-anti-Linc00707 specifically blocks Linc00707-U2AF2 complex formation, reversing its tumor-promoting and autophagy-suppressing functions. Thus, targeting Linc00707 represents a promising therapeutic strategy for TNBC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
SF3B4-QKI splicing complex generates circ-FNDC3B and mediates breast cancer inhibition
Circular RNA, usually produced through a back-splicing process, is a type of single-stranded RNA that is covalently bonded. Our research indicated that a spliceosome composed of SF3B4 and QKI promoted the back-splicing of FNDC3B, thereby promoting the generation of Circ-FNDC3B. Circ-FNDC3B is underexpressed in breast cancer and is characterized by a high metastatic risk. In addition, Circ-FNDC3B expression was reduced in breast cancer with larger tumor diameter, later clinical staging, and lymph node metastasis(LNM). The secondary structure of Circ-FNDC3B, specifically the 356-425 bp sequence, interacts with the biotin carboxylase domain of pyruvate carboxylase(PC), inhibiting the activity of PC. Low expression of Circ-FNDC3B enhances the activity of pyruvate carboxylase, thereby facilitating cell proliferation. The underlying mechanism involves the promotion of aspartate synthesis and the acceleration of the citrate - pyruvate cycle. This, in turn, promotes NADPH synthesis, thus alleviating the oxidative damage induced by reactive oxygen species (ROS). Furthermore, in human breast cancer organoids and a mouse model of lung metastasis, we have further validated that exogenous expression of circular RNA FNDC3B (Circ-FNDC3B) can inhibit the activity of pyruvate carboxylase (PC), thereby suppressing tumor proliferation and promoting tumor cell apoptosis. In general, upregulating the expression of circular Circ-FNDC3B can impede the progression of breast cancer. Implications: This study reveals significant heterogeneity of expression of circular RNAs commonly used to identify breast cancer metastasis, and confirms that circular RNAs affect the metabolic state of breast cancer through their binding proteins.
- 16 March 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
SF3B4-QKI splicing complex generates circ-FNDC3B and mediates breast cancer inhibition
Circular RNA, usually produced through a back-splicing process, is a type of single-stranded RNA that is covalently bonded. Our research indicated that a spliceosome composed of SF3B4 and QKI promoted the back-splicing of FNDC3B, thereby promoting the generation of Circ-FNDC3B. Circ-FNDC3B is underexpressed in breast cancer and is characterized by a high metastatic risk. In addition, Circ-FNDC3B expression was reduced in breast cancer with larger tumor diameter, later clinical staging, and lymph node metastasis(LNM). The secondary structure of Circ-FNDC3B, specifically the 356-425 bp sequence, interacts with the biotin carboxylase domain of pyruvate carboxylase(PC), inhibiting the activity of PC. Low expression of Circ-FNDC3B enhances the activity of pyruvate carboxylase, thereby facilitating cell proliferation. The underlying mechanism involves the promotion of aspartate synthesis and the acceleration of the citrate - pyruvate cycle. This, in turn, promotes NADPH synthesis, thus alleviating the oxidative damage induced by reactive oxygen species (ROS). Furthermore, in human breast cancer organoids and a mouse model of lung metastasis, we have further validated that exogenous expression of circular RNA FNDC3B (Circ-FNDC3B) can inhibit the activity of pyruvate carboxylase (PC), thereby suppressing tumor proliferation and promoting tumor cell apoptosis. In general, upregulating the expression of circular Circ-FNDC3B can impede the progression of breast cancer. Implications: This study reveals significant heterogeneity of expression of circular RNAs commonly used to identify breast cancer metastasis, and confirms that circular RNAs affect the metabolic state of breast cancer through their binding proteins.